# Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers

> **NCT02391181** · PHASE1 · COMPLETED · sponsor: **Azad Pharma AG** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Iron Sucrose Azad
- **DRUG:** Venofer®

## Key facts

- **NCT ID:** NCT02391181
- **Lead sponsor:** Azad Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02391181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02391181, "Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02391181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*